Renoproteccíon y cardioproteccíon asociadas al uso de inhibidores de SGLT-2

##plugins.themes.bootstrap3.article.main##

Rodrigo Braga Pacheco
Ana Cláudia Dias Malta
Izabella Gomes Félix
Ana Luiza Ferreira Silva
Ana Clara Santos de Godoi
Sofia Campos da Rocha
Isadora Sena Torres Queiroz
Marcelo Ribeiro Bastos

Resumen

Objetivo: Evaluar los beneficios de protección renal y cardiovascular del uso de inhibidores de SGLT-2. Revisión bibliográfica: La dapaglifozina y otros fármacos de esta clase se encargan de inhibir el cotransportador sodio-glucosa 2 y esto provoca una reducción de la glucemia, un aumento de la función secretora de las células β pancreáticas y un aumento de la natriuresis. En este contexto, un conjunto de estudios apuntaron a una disminución del riesgo de desarrollar insuficiencia renal (IR), insuficiencia cardiaca (IC), así como un aumento de la supervivencia de estos pacientes y de los pacientes con DM2 que pueden o no tener complicaciones relacionadas con la estos sistemas. Consideraciones finales: los inhibidores de SGLT-2 mostraron evidencia de mecanismos relacionados con la renoprotección como inducción de glucosuria, aumento de la transición lineal entre reabsorción y excreción renal de glucosa y cardioprotectores como disminución de la pre y poscarga, mejoría de la función diastólica y, por lo tanto, vale la pena analizando sus posibles efectos secundarios para que los riesgos y beneficios avalen su uso en pacientes renales y/o cardíacos.

##plugins.themes.bootstrap3.article.details##

Cómo citar
PachecoR. B., MaltaA. C. D., FélixI. G., SilvaA. L. F., GodoiA. C. S. de, RochaS. C. da, QueirozI. S. T., & BastosM. R. (2023). Renoproteccíon y cardioproteccíon asociadas al uso de inhibidores de SGLT-2. Revista Eletrônica Acervo Médico, 23(5), e12579. https://doi.org/10.25248/reamed.e12579.2023
Sección
Revisão Bibliográfica

Citas

1. BANERJEE S e GROBELNA A. Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetic Nephropathy: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.

2. BOCCHI EA, et al. Tópicos Emergentes em Insuficiência Cardíaca: Inibidores do Cotransportador Sódio-Glicose 2 (iSGLT2) na IC. Arquivos Brasileiros de Cardiologia, 2021; 116(2): 355-358.

3. DEKKERS CCJ, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab., 2018; 20(8): 1988-1993.

4. de JONG MA, et al. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clin J Am Soc Nephrol., 2019; 14(1): 66-73.

5. DEKKERS CCJ, et al. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep., 2018; 18(5): 27.

6. FIORETTO P, et al. DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab., 2018; 20(11): 2532-2540.

7. GONZALEZ DE, et al. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Rev Assoc Med Bras (1992), 2020; 66Suppl 1(Suppl 1): s17-s24.

8. GUPTA M, et al. The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. Ther Clin Risk Manag., 2021; 17: 823-830.

9. HANDELSMAN Y. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther., 2019; 36(10): 2567-2586.

10. HEERSPINK HJL, et al. DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J., 2021; 42(13): 1216-1227.

11. HEERSPINK HJL, et al. DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int., 2022; 101(1): 174-184.

12. KITADA M, et al. Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetol Int., 2020; 11(3): 245-251.

13. KLUGER AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol., 2019; 18(1): 99.

14. McMURRAY JJV, et al. DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Fail, 2021; 9(11): 807-820.

15. McEWAN P, et al. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab., 2021; 23(4): 1020-1029.

16. NEUEN BL, et al. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant, 2020; 35(Suppl 1): i48-i55.

17. NINČEVIĆ V, et al. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Int J Mol Sci., 2019; 20(23): 5831.

18. RHEE JJ, et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab., 2020; 22 Suppl 1(Suppl 1): 46-54.

19. SCHOLTES RA, et al. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care, 2021; 44(2): 440-447.

20. QIU M, et al. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res., 2021; 18(2): 14791641211011016.

21. WHEELER DC, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant, 2020; 35(10): 1700-1711.